טוען...
FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
Patients with intrahepatic cholangiocarcinoma (iCCA) face a highly dismal prognosis, due to late stage diagnosis, the relative chemoresistance of the disease, and an overall limited portfolio of established therapeutic concepts. In recent years, a number of next generation sequencing studies have pr...
שמור ב:
| הוצא לאור ב: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7498964/ https://ncbi.nlm.nih.gov/pubmed/32983265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920953293 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|